Bausch + Lomb: FDA 510(k) clearances across all its applicant names
FDA lists 290 510(k) clearances, 34 PMA and 0 De Novo decisions across the 7 applicant names Caduvo groups under Bausch + Lomb, first 1976, latest 2026. Median 510(k) review time across these names: 80 days. Since 2017 the median was 97 days, against 107 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 6 | 190 |
| 2013 | 7 | 135 |
| 2014 | 6 | 123 |
| 2015 | 4 | 54 |
| 2016 | 3 | 147 |
| 2017 | 8 | 62 |
| 2018 | 3 | 51 |
| 2019 | 2 | 78 |
| 2020 | 3 | 166 |
| 2021 | 3 | 177 |
| 2022 | 1 | 106 |
| 2023 | 2 | 298 |
| 2024 | 3 | 186 |
| 2025 | 0 | — |
| 2026 | 3 | 56 |
The 7 FDA applicant names in this group
| Applicant name | 510(k) clearances | PMA | De Novo | Years |
|---|---|---|---|---|
| Bausch & Lomb, Inc. | 138 | 32 | 0 | 1977–2026 |
| Storz Instrument Co. | 101 | 0 | 0 | 1976–1998 |
| Chiron Vision Corp. | 34 | 0 | 0 | 1980–1997 |
| Technolas Perfect Vision GmbH | 10 | 1 | 0 | 1999–2020 |
| Bausch & Lomb Pharmaceutical, Inc. | 6 | 0 | 0 | 1988–1990 |
| Bausch & Lomb Healthcare and Optics Worldwide | 1 | 0 | 0 | 1995–1995 |
| Bausch & Lomb Surgical, Inc. | 0 | 1 | 0 | — |
Review time against the same product codes
Since 2017, 510(k)s cleared under these names took a median 97 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 107 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| HQC | Unit, Phacofragmentation | 47 | 47 |
| LPL | Lenses, Soft Contact, Daily Wear | 21 | 21 |
| LPN | Accessories, Soft Lens Products | 20 | 20 |
| HQL | Intraocular Lens | 17 | 0 |
| HQE | Instrument, Vitreous Aspiration And Cutting, Ac-Powered | 16 | 16 |
| MSS | Folders And Injectors, Intraocular Lens (Iol) | 13 | 13 |
| HNO | Keratome, Ac-Powered | 9 | 9 |
| OOE | Ophthalmic Femtosecond Laser | 9 | 9 |
| HQD | Lens, Contact (Other Material) - Daily | 8 | 8 |
| MOE | Collagen Corneal Shield | 8 | 8 |
Plus 90 more product codes.
Review panels
- Ophthalmic (260)
- General and Plastic Surgery (23)
- Radiology (8)
- Clinical Chemistry (6)
- Dental (6)
- Ear, Nose and Throat (6)
- Neurology (5)
- General Hospital (4)
- Orthopedic (2)
- Gastroenterology and Urology (1)
- Pathology (1)
Most recent Bausch + Lomb 510(k) clearances
| 510(k) | Device | Applicant name | Product code | Decision date | Review days |
|---|---|---|---|---|---|
| K262941 | Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens | Bausch & Lomb, Inc. | LPL | 2026-10-16 | 56 |
| K261264 | Stellaris Elite vision enhancement system; Posterior and Combined Procedure Pack(s): 23 ga. Posterior Elite Pack (SE5423); 23 ga. Bi-Blade Vitreous Cutter Posterior Stellaris Elite Pack (SE5423B); 25 ga. Posterior Elite Pack (SE5425); 25 ga. Bi-Blade Vitreous Cutter Posterior Stellaris Elite Pack (SE5425B); 27 ga. Bi-Blade Vitreous Cutter Posterior Stellaris Elite Pack (SE5427B); 23 ga. Bi-Blade+ Vitreous Cutter Posterior Stellaris Elite Pack (SE5423BB+); 25 ga. Bi-Blade+ | Bausch & Lomb, Inc. | HQC | 2026-05-15 | 29 |
| K252052 | Stellaris Elite vision enhancement system (BL11145, BL14455, BL15455, SE14565, SE15565, SE14565E, SE15565E) | Bausch & Lomb, Inc. | HQC | 2026-03-25 | 267 |
| K242389 | EyeGility Inserter for Preloaded enVista IOLs | Bausch & Lomb, Inc. | MSS | 2024-10-10 | 59 |
| K240169 | Stellaris Elite vision enhancement system (BL11145, BL14455, BL15455) | Bausch & Lomb, Inc. | HQC | 2024-07-26 | 186 |
| K232084 | Stellaris Elite vision enhancement system | Bausch & Lomb, Inc. | HQC | 2024-02-26 | 228 |
| K230954 | Samfilcon B Custom Contact Lens | Bausch & Lomb, Inc. | LPL | 2023-11-17 | 227 |
| K220613 | Bausch + Lomb (kalifilcon A) Soft (hydrophilic) Contact Lens, Bausch + Lomb (kalifilcon A) Soft (hydrophilic) Contact Lens for Astigmatism, and, Bausch + Lomb (kalifilcon A) Soft (hydrophilic) Contact Lens for Presbyopia | Bausch & Lomb, Inc. | LPL | 2023-03-08 | 370 |
| K222541 | Bausch + Lomb Preservative Free Lubricating and Rewetting Drops | Bausch & Lomb, Inc. | LPN | 2022-12-06 | 106 |
| K211786 | Independent Corneal Viewing Chamber (IVC-21) | Bausch & Lomb, Inc. | LYX | 2021-12-03 | 177 |
280 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| P240005 | PMA | enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL) | 2024-10-10 |
| P170035 | PMA | Bausch + Lomb Ultra (samfilcon A) Contact Lenses | 2018-04-30 |
| P080021 | PMA | XACT FOLDABLE HYDROPHOBIC ACRYLIC ULTRAVIOLET LIGHT-ABSORBING POSTERIOR CHAMBER INTRAOCULAR LENS (IOL) | 2009-02-02 |
| P060022 | PMA | AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS,MODEL ADAPT | 2008-09-05 |
| P010062 | PMA | EUCLID SYSTEMS ORTHOKERATOLOGY (OPRIFOCON A) CONTACT LENS FOR OVERNIGHT WEAR | 2004-06-07 |
Recalls
93 product recalls in 37 recall events under these names; 3 initiated in the last five years.
10 product recalls in 6 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 0 initiated in the last five years. Most often: Anika Therapeutics (4), Alden Optical (2), Bausch & Lomb Inc Irb (2).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
ClinicalTrials.gov lists 109 device studies (4 active or recruiting) with an industry lead sponsor under the 3 sponsor names below. Most recent:
- NCT07377474: A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism (Bausch & Lomb Incorporated; Not yet recruiting, started 2026-04)
- NCT06785194: Revive Toric RWE Study (Bausch & Lomb Incorporated; Withdrawn, started 2026-03)
- NCT06618547: Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy (Bausch & Lomb Incorporated; Not yet recruiting, started 2025-11)
- NCT06997003: Evaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2 (Bausch & Lomb GmbH; Recruiting, started 2025-06-16)
- NCT06767917: A Post-Market Clinical Follow-Up on Safety and Performance of the Ophthalmic Viscoelastic Devices Eyefill SC and Eyefill MB (Bausch & Lomb GmbH; Completed, started 2024-11-26)
| Lead sponsor name on ClinicalTrials.gov | Device studies |
|---|---|
| Bausch & Lomb Incorporated | 96 |
| Technolas Perfect Vision GmbH | 11 |
| Bausch & Lomb GmbH | 2 |
Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.
Parent company SEC filings
Bausch & Lomb Corp (BLCO): EDGAR filings, CIK 1860742. The parent's SEC registrant is entered by hand for this group, not matched by name.
How this group is built
Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
Storz Instrument Co (1986, ophthalmic surgery; unrelated to KARL STORZ), Chiron Vision (1997), Technolas Perfect Vision (2013). Includes filings made before each acquisition.
Sources
Frequently asked questions
How many FDA 510(k) clearances are listed across Bausch + Lomb's applicant names?
FDA lists 290 510(k) clearances, 34 PMA and 0 De Novo decisions across the 7 applicant names Caduvo groups under Bausch + Lomb, first 1976, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.
Which FDA applicant names does Bausch + Lomb file under?
The names with the most 510(k) clearances in this group are Bausch & Lomb, Inc. (138); Storz Instrument Co. (101); Chiron Vision Corp. (34); Technolas Perfect Vision GmbH (10); Bausch & Lomb Pharmaceutical, Inc. (6). The full list of 7 names is on this page.
How long does FDA take to clear Bausch + Lomb 510(k)s?
The median time from FDA receipt to decision across 510(k)s cleared under these names is 80 days. Since 2017 the median was 97 days, against 107 days for all cleared 510(k)s in the same product codes.
Does the Bausch + Lomb count include acquired companies?
Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.
How many device clinical trials does Bausch + Lomb sponsor?
ClinicalTrials.gov lists 109 device studies (4 active or recruiting) with an industry lead sponsor under 3 sponsor names Caduvo groups under Bausch + Lomb. ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.
Next steps
- See all 290 Bausch + Lomb clearances with predicates and recalls
- Run predicate analysis for product code HQC, Bausch + Lomb's most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.
All parent companies · FDA device companies by applicant name · FDA product code lookup